✦ LIBER ✦

Benefit–Risk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation

✍ Scribed by Meyer dos Santos, Sascha; Harder, Sebastian

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of Dabigatran for Str

✍ González-Juanatey, José R.; Álvarez-Sabin, José; Lobos, José M.; Martínez-Rubio, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 355 KB

Economic evaluation of dabigatran for st

✍ Silva Miguel, Luís; Rocha, Evangelista; Ferreira, Jorge 📂 Article 📅 2013 🏛 Elsevier ⚖ 703 KB

Antithrombotic therapy for stroke preven

✍ Mark J Alberts; John W Eikelboom; Graeme J Hankey 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 327 KB

Dabigatran in atrial fibrillation: balan

✍ Deirdre A Lane; Gregory YH Lip 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 181 KB

PCV60 Cost-Effectiveness of Dabigatran f

✍ D. Tilden; P. Germanos; J. Gordon; L. Tocchini; B. Monz 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Cost-Effectiveness Analysis of Apixaban

✍ Betegón Nicolás, L.; Escolar Albaladejo, G.; Canal Fontcuberta, C.; de Salas-Can 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB